A Phase 2 interventional study of HLX22 and Trastuzumab in HER2-Positive, Limited Metastatic and Gastric Cancer, sponsored by Shanghai Zhongshan Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Shanghai Zhongshan Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Stomach Neoplasms by Shanghai Zhongshan Hospital — 13 open to participants now, 14 under way, none of them phase 3. Stomach Neoplasms · Shanghai Zhongshan Hospital.
Among the 31 studies in Stomach Neoplasms by Shanghai Zhongshan Hospital, this one is the 16th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2026, is one of 9 in phase 2, reaches primary completion later than 11 of the 13 other live ones, and was the 31st registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →13 of the 31 studies in Stomach Neoplasms by Shanghai Zhongshan Hospital are open now, in 1 country. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18–79
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
Shanghai Zhongshan Hospital · Sites in China
Ages 18–74
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 2
First in 2008; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 48 across the 19 interventional studies, 462 across the 12 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Zhongshan Hospital is the lead sponsor of 653 studies on the registry; 292 are open to participants now.
2 of the studies in Stomach Neoplasms by Shanghai Zhongshan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05311189Shanghai Zhongshan HospitalStudy of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer | 2026-12-31 |
| NCT07333573Shanghai Zhongshan HospitalA Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Stomach Neoplasms by Shanghai Zhongshan Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, open-label, exploratory study evaluating the efficacy and safety of HLX22 in combination with first-line systemic therapy in patients with HER2-positive, limited metastatic, unresectable gastric or gastroesophageal junction adenocarcinoma. Patients will receive HLX22 combined with trastuzumab and XELOX chemotherapy, with or without the PD-1 inhibitor HLX10 according to PD-L1 and mismatch repair status. The primary endpoint is objective response rate assessed by RECIST v1.1.
This study is a prospective, open-label, exploratory clinical trial designed to evaluate the efficacy and safety of HLX22 in combination with first-line systemic therapy in patients with HER2-positive, limited metastatic, unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Eligible patients will receive HLX22 in combination with trastuzumab and XELOX chemotherapy, with or without the PD-1 inhibitor HLX10 according to PD-L1 combined positive score (CPS) and mismatch repair (MMR) status. The primary endpoint of the study is objective response rate (ORR) assessed according to RECIST version 1.1. Secondary endpoints include disease control rate, conversion surgery rate, pathological response, R0 resection rate, progression-free survival, disease-free survival, overall survival, and safety.
This study aims to explore whether intensification of HER2-targeted therapy combined with chemotherapy, with or without immunotherapy, may improve tumor response and facilitate potential conversion to surgical resection in a selected population of patients with limited metastatic disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet all of the following inclusion criteria:
Limited metastatic disease assessed by a multidisciplinary team (MDT) and deemed unresectable.
Limited distant metastasis is defined as meeting only a or a single b ± a, as follows:
a. Abdominal non-regional lymph node metastases, including metastases to the superior mesenteric artery lymph nodes, middle colic artery lymph nodes, para-aortic or retroperitoneal lymph nodes; b1. Limited peritoneal metastasis (P0CY1 or P1a or P1b):P0CY1 is defined as the presence of malignant tumor cells detected by cytological examination of ascites or peritoneal lavage fluid during laparoscopic exploration, without macroscopic visible peritoneal metastatic lesions;P1a is defined as peritoneal metastases limited to areas adjacent to the stomach, greater omentum, lesser omentum, anterior leaf of the transverse mesocolon, pancreatic capsule, and spleen;P1b is defined as peritoneal metastases in the upper abdomen, specifically involving the parietal peritoneum above the umbilicus and the visceral peritoneum above the transverse colon; b2. Liver metastases, with no more than 5 metastatic lesions; b3. Lung metastases, unilateral involvement only, with no more than 5 metastatic lesions; b4. Unilateral or bilateral ovarian metastases; b5. Unilateral or bilateral adrenal gland metastases; b6. Extra-abdominal lymph node metastases confined to a single region, such as cervical lymph nodes, supraclavicular lymph nodes, or mediastinal lymph nodes; b7. Bone metastases confined to a single radiation field; b8. Other limited distant metastases as determined by evaluation of the study team.
Adequate organ function, meeting the following criteria (within 14 days prior to randomization, without receiving blood transfusion, albumin, recombinant human thrombopoietin, or colony-stimulating factor [CSF] treatment):
Exclusion Criteria:
Subjects meeting any of the following exclusion criteria will not be eligible for this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with PD-L1 combined positive score (CPS) ≥5 and/or deficient mismatch repair (dMMR) tumors will receive HLX22 in combination with trastuzumab, XELOX chemotherapy, and the PD-1 inhibitor HLX10 as first-line treatment.
Drug: HLX22 · Drug: Trastuzumab · Drug: XELOX Chemotherapy · Drug: HLX10
Participants with PD-L1 combined positive score (CPS) \<5 and proficient mismatch repair (pMMR) tumors will receive HLX22 in combination with trastuzumab and XELOX chemotherapy as first-line treatment.
Drug: HLX22 · Drug: Trastuzumab · Drug: XELOX Chemotherapy
HLX22 is administered intravenously every 3 weeks in combination with standard first-line systemic therapy, according to the protocol.
Trastuzumab is administered intravenously in combination with HLX22 and chemotherapy. A loading dose of 8 mg/kg is given at the first administration, followed by maintenance doses of 6 mg/kg every 3 weeks.
XELOX chemotherapy consists of:Oxaliplatin administered intravenously on Day 1 of each 3-week cycle;Capecitabine administered orally twice daily on Days 1-14 of each 3-week cycle.
HLX10, a PD-1 inhibitor, is administered intravenously every 3 weeks in participants assigned to the CPS ≥5 or dMMR arm, according to the study protocol.
Objective Response Rate
Objective response rate (ORR) is defined as the proportion of participants achieving a complete response (CR) or partial response (PR), as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Time frame: From the start of study treatment to the first tumor response assessment after 4 cycles (each cycle is 21 days; approximately 12 weeks), or up to 6 cycles (approximately 18 weeks) for participants receiving extended treatment.
Disease Control Rate (DCR)
Disease control rate (DCR) is defined as the proportion of participants achieving complete response (CR), partial response (PR), or stable disease (SD) according to RECIST version 1.1.
Time frame: From the start of study treatment to the first tumor response assessment after completion of systemic therapy (approximately 12-18 weeks).
Conversion Surgery Rate
Conversion surgery rate is defined as the proportion of participants who undergo surgical resection with curative intent following systemic therapy, as determined by multidisciplinary team (MDT) assessment.
Time frame: From the start of study treatment to the time of surgical decision and performance, typically after completion of systemic therapy and prior to disease progression (approximately 12-20 weeks).
Pathological Complete Response (pCR)
Pathological complete response (pCR) is defined as the absence of residual viable tumor cells in the resected primary tumor and sampled lymph nodes on postoperative pathological examination.
Time frame: At the time of surgical resection (approximately 12-20 weeks after the start of study treatment), with pCR determined by postoperative pathological examination.
Major Pathological Response (MPR)
Major pathological response (MPR) is defined as the presence of ≤10% residual viable tumor cells in the resected primary tumor specimen, as determined by postoperative pathological assessment.
Time frame: At surgical resection, planned 4-6 weeks after completion of 4 or 6 treatment cycles (21 days per cycle), corresponding to approximately 16-18 or 22-24 weeks after treatment initiation, respectively.
Progression-Free Survival (PFS)
Progression-free survival (PFS) is defined as the time from the date of enrollment to the first documented disease progression according to RECIST v1.1 or death from any cause, whichever occurs first.
Time frame: From the date of enrollment to the first documented disease progression according to RECIST v1.1 or death from any cause, whichever occurs first, assessed up to 25 months.
Disease-Free Survival
Disease-free survival (DFS) is defined as the time from the date of surgery to the first documented tumor recurrence, metastasis, or death from any cause, whichever occurs first. DFS will be assessed only in participants who undergo surgery.
Time frame: From the date of surgery to the first documented tumor recurrence, metastasis, or death from any cause, whichever occurs first, assessed up to approximately 22 months.
Overall Survival
Overall survival (OS) is defined as the time from the date of enrollment to death from any cause. Participants lost to follow-up will be censored at the date of their last follow-up.
Time frame: From the date of enrollment to death from any cause, assessed up to 25 months; participants lost to follow-up will be censored at the date of last follow-up.
Adverse Events
Safety will be assessed by the incidence, severity, and type of adverse events (AEs) and serious adverse events (SAEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 (or version specified in the protocol).
Time frame: From the first dose of study treatment until 30 days after the last dose of study treatment.
No study locations are listed for this record.
Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.
Of 295 non-industry phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 76. This study's planned 12 months is below that.
Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.